Member Info for notaflipper

I think we are expecting a Trading Update next week which should be better

The timeline is detailed in the 14th Oct RNS

So as summary:
- 28 October 2020 is the Early Deadline for acceptance
- 3 November 2020 is the Final Deadline
- 5 November 2020 is the EUR Meetings, GBP Meeting and SEK Meeting where one votes in person or via nominee
- Announcement expected to be as soon as reasonably practicable after the Meetings of conditional acceptance (or NOT) of Existing EUR Notes exchanged pursuant to the Exchange Offer and results of Consent Solicitations

Due to COVID restrictions there was some debate, and the generous terms offered in the Exchange Offer, whether the meetings on 5th would be required. Or whether all the votes would be in by Early/Final deadline and we would get an early announcement. SP raising in anticipation suggests some confidence. Noticeable that SP is below Artemis purchase.

Sell now and come back in 3 years time. Why you checking for any sp reaction today then? It is dead money.

I think shareholders here have demonstrated enough patience. It's time shareholder value was finally delivered and excuses were paused

With Barclays recovering most of its losses from the last week to start closing in on its month high, it is surprising that the sp is not higher. Without the wider market worries the sp should be in the 70s - 80s. Hopefully we shall se a resumption of the upward trend in the run up to next week's announcement

Apologies I have been wrong footed now twice by IR: (1) Believing that no monthly update was due at the beginning of the month and then getting the unexpected earlier release of the Q3 update plus bond refinancing news; and (2) believing that a further trading update was due today on other matters hence the notification not being corrected by IR.

Now that we are slowly moving on from our morning hissy fit we need to bear in mind that (1) the Trading Update came EARLIER and was not a NO SHOW and that (2) the Trading Update was GOOD.

The highlights as below:
Q3 update confirmed positive momentum with £348 million of cash and headroom on current debt facilities and collections effectiveness improving to 95% of pre-Covid expectations in Q3. Return to profitability subscribed to by recent Holdings RNS of Artemis. This all suggests that the Group annualised impairment as a percentage of revenue 38.1% (HY 2020:37.5%) will not be actually that bad. Funny thing is that the sp has fallen from its pre-Covid levels more than this impairment performance.

Although the news may suggest that the only sane course of action nowadays is to put one's money and build a bunker from where to ward off the infected masses; the Q3 trading update does realistically show quite a bit of impairment built into the annual projections. Whilst at the same time showing that collections effectiveness is actually back to pre-Covid levels. Further to that the sp is still trading at a discount to this valuation.

I am mindful that the drop earlier in the year was due to worries about the financial robustness however with the 14th Oct RNS we can see that these worries have been reduced in the last few months with increasing headroom and will be finally resolved realistically by the 5th November. As such this should give us some confidence in the underlying strength of the SP.

Think you need to report the link as when I clicked on it the status said that "The page does not exist".

Still holding. However the sp retrace, with the lack of news flow and low volume is very frustrating. The risk of downside does not seem to be as bad as earlier in the year to whether this. However I am hoping that some news comes which together with the lack of free float would prompt a similar sp rise and at a similar pace as earlier in the year.

Apologies I have been wrong footed now twice by IR: (1) Believing that no monthly update was due at the beginning of the month and then getting the unexpected earlier release of the Q3 update plus bond refinancing news; and (2) believing that a further trading update was due today on other matters hence the notification not being corrected by IR.

Now that we are slowly moving on from our morning hissy fit we need to bear in mind that (1) the Trading Update came EARLIER and was not a NO SHOW and that (2) the Trading Update was GOOD.

The highlights as below:
Q3 update confirmed positive momentum with £348 million of cash and headroom on current debt facilities and collections effectiveness improving to 95% of pre-Covid expectations in Q3. Return to profitability subscribed to by recent Holdings RNS of Artemis. This all suggests that the Group annualised impairment as a percentage of revenue 38.1% (HY 2020:37.5%) will not be actually that bad. Funny thing is that the sp has fallen from its pre-Covid levels more than this impairment performance.

Although the news may suggest that the only sane course of action nowadays is to put one's money and build a bunker from where to ward off the infected masses; the Q3 trading update does realistically show quite a bit of impairment built into the annual projections. Whilst at the same time showing that collections effectiveness is actually back to pre-Covid levels. Further to that the sp is still trading at a discount to this valuation.

I am mindful that the drop earlier in the year was due to worries about the financial robustness however with the 14th Oct RNS we can see that these worries have been reduced in the last few months with increasing headroom and will be finally resolved realistically by the 5th November. As such this should give us some confidence in the underlying strength of the SP.

This BB is now joker of swing traders

It is difficult to understand the SP shake despite some of the domestic COVID headlines given that a potential trading update is expected this week and results of the bond financing are due on the 5th November. Although enjoying a brief spike after the 14th October announcement the bond % has returned to its trend over the last few months of 90% suggesting some underlying confidence that the bonds will be refinanced.
https://www.londonstockexchange.com/stock/47AV/international-personal-finance-plc/company-page

With Barclays results earlier in the week suggesting that Financials are looking past the Covid woes of this year to the expected news of a vaccine we should expect the same improving outlook.

Q3 update confirmed positive momentum with £348 million of cash and headroom on current debt facilities and collections effectiveness improving to 95% of pre-Covid expectations in Q3. Return to profitability subscribed to by recent Holdings RNS of Artemis. This all suggests that the Group annualised impairment as a percentage of revenue 38.1% (HY 2020:37.5%) will not be actually that bad. Funny thing is that the sp has fallen from its pre-Covid levels more than this impairment performance.

Topped up with circa £8k purchase this morning on the dip.

I think Sorcerer summed up the confusion which is that the Company has stated that they are in talks at both a National and Local level to contribute to the moonshot testing plans. This aims at 500k tests per day whereas the capacity plans, if only based on in-house processing, has a capacity of 20k per month. Hence the confusion despite the clear statement of testing capacity. It doesn't look like the news of a vaccine has impaired NCYT's share price it has to be said perhaps because of Sor Patrick Vallance's statements to Parliament last week that a vaccine would not eradicate COVID-19 as this would just become endemic to society, like the common cold, and we would have to take tests and vaccines as part of normal course.

Yes one would have expected a standalone Quarterly update. I find the Director purchases (which have been rare) and Steve Myers share purchase in retrospect very strange given that they would have known better the impairment. So why not await till after the TU? Key for me is the testing, if any, that is being done externally. The promotion of the Covid-19 business in the Company's marketing material is not reflected in these figures. The expected uptake also seems to be at odds with Yourgene having one of the best PCR tests on the market, which are the 'gold standard' compared to other tests. Apparently this is all only good for 20k tests a month which is just simply baffling. Looking forward to any further clarification to paper over the confusion/disappointment. It would be interesting to see the forward looking statements for the new Clarigene test, which was also not referenced in the commentary, and also the commercialisation of the IONA Nx. As ever hopeful.

P.S. It has to be said that the LSE website was frustrating and crap enough. However the recent innovation of the thread views is just frustrating to another level.

I agree with this statement "The £1m monthly revenue is from the in-house testing capacity only, but we are still no clearer, as far as I can tell, as to how much we will earn from the Clarigene sales to external providers."

I remain hopeful of some further news coming, perhaps naively given the opportunity loss here. Should be interesting if there is any updates from Align etc following.

I believe we are expecting two different updates: (1) Half Yearly Update; and (2) Quarterly Covid-19 testing update. Obviously we can add new product updates in terms of new Covid-19 tests or oncology. Otherwise further news on the IONA Nx Commercialisation and Coastal Genomics integration. However in terms of the two updates mentioned it would be surprising if this was rolled into just one RNS. Also following the pattern from the AGM there will probably be a series of RNS to avoid a slip-back and create a forward sp momentum.
Best of luck to All and LTHs.

SP pick-up may suggest further news before next Thursday 29th.

My understanding is that the early deadline by when holders of existing GBP, SEK and EUR notes must give their voting instruction or exchange instruction by Wednesday 28th. The final deadline is the 3rd Nov. Otherwise they must attend the GBP, SEK and EUR meeting on the 5th and vote in person. It would suggest that if all votes and exchanges instructions are received before the 5th then this meeting on the 5th may be unnecessary given the present circumstances.

...should be quite interesting with a Trading Statement due next Thursday on the 29th and then the results of the debt refinance approval on Wednesday 5th Nov. Would be surprised we don't get to 70p beforehand.

...is the global footprint and depth of product portfolio being developed which I suspect is still frankly difficult to appreciate.

In a simple example due to the acquisitive growth strategy newbies cannot just look at the https://www.yourgene-health.com/ website to understand the company simply because of the complexity and range of the products which has also I believe flummoxed the investment research here.

You also need to look at https://www.elucigene.com/ and https://www.coastalgenomics.com/ to understand the full range and depth of the product range as this has yet to be migrated to the YourGenene website.

In another example the recent RNS on DPYD testing in Wales would give the impression that this test was not more pervasive than it is. So in another simple example this is also being done for Manchester University NHS trust and the Elucigene had built up an impressive list of distributors which once again are not reflected on the YourGene website (https://www.elucigene.com/distributors/)

With the Align research note coming out in August and the IONA® Nx and DPYD commercialisation thereafter I believe that separate to today's COVID-19 testing capacity increases, this commercialisation (especially in the US) has not been reflected in the DCF target valuation of 26.6 3p.

@themorg thanks for the wise words. Filter list has been a god send this morning to focus on the posters that matter

Address of 2nd lab. Bigger footprint. Question is whether they will add more and if they are co-opting in externally from their 300+ partner lab network.
https://www.cqc.org.uk/provider/1-2037577564/services

Some highlights: One of the best sensitivity tests (5 LoD copies per reaction) and dual viral RNA targets making it one of the most accurate COVID-19 antigen tests out there.

Time sequence : Preparation time for 96 samples is <30mins.

Assay runtime is 120 mins. This is broken up as follows:
-> 25 mins for isolation
-> 80 mins for cDNA synthesis from RNA (DNA extraction step)
-> 15 mins for data analysis

NOTE: Test itself though @ still with manual workflow

Turnaround though is 24-48 hrs to provide for sample receipt and job queuing envelope.

New test (coming soon ~ yeah I know) is a test called Clarigene Pathogen Necleic Acid Extraction kit. This is the response to challenger tests to the PCR tests. Their marketing material made a big thing of their tests having magnetic beads which allowed for faster nucleic extraction. This announcement, before the COVID test was CE-IVD marked and still a prototype had the effect on the sp of Whooosh. Like the Nike symbol @ -90% rotation

Happily this new test has not been RNS'd! Gratefully we got instead yesterday a RNS on a potential Genomics Servicing test with Cytox's genoSCORE for Alzheimer's disease (also at prototype stage which will come to market much later than the Clarigene Pathogen Necleic). IR prioritised this one. Very Good.

Interesting observations about saliva testing as per disposable Boots test in video as mentioned it is being looked at but is not as accurate as lamp PCR test which is still considered by Public Health England as the 'gold standard'.

Other parts to note of this new test is high automation and room temperature processing possible. Think again where else you've heard that before. Yes, Whooosh. YGEN's sp since the AGM is looking like Whooosh in reverse.

@45.31 the Paul Docherty as Business Development Director, fields question which asks "Do you have the capacity to assist in the moon-shot programme?" His response "The answer is "Yes", we do have the capacity and "Yes" we have been in contact with the Department of Health & Social Care for a few weeks now at both the Regional and National Level and expect to announce something in the new future" [apologies for slight paraphrasing here]

@46.20 Bhavika Patel (quite pretty) says "we will not be impacted by new Tier 3 restrictions in Manchester as we have the capacity to deal with this. If anything there may be more tests coming our way. But we have the capacity to deal with this."

YourGene say they are testing only 10k+ tests per month but Cambridge Clinical Laboratories (CCL) is also using their Clarigene test. So not sure if this 10k+ tests include external lab processing. CCL has 3 Department of Health and Social Care contracts which I suspect necessitates more than 10k tests per month.

I have been a bit surprised by the lack of sp momentum in the last couple of days and can only imagine that the sp is being held back for other IIs to load up on.